skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8838

Antiplatelet agents and proton pump inhibitors – personalizing treatment

Review

(2051) Views  (800) Full article downloads

Authors: Eugene Lin, Rajiv Padmanabhan, Majaz Moonis

Published Date June 2010 Volume 2010:3 Pages 101 - 109
DOI: http://dx.doi.org/10.2147/PGPM.S7298

Eugene Lin, Rajiv Padmanabhan, Majaz Moonis

Department of Neurology, University of Massachusetts Medical School and UMass Memorial Medical Center, Worcester, Massachusetts, USA

Introduction: Antiplatelet therapy remains one of the cornerstones in the management of noncardioembolic ischemic stroke. However, a significant percentage of patients have concomitant gastroesophageal reflux or peptic ulcer disease that requires acid-reducing medications, the most powerful and effective being the proton pump inhibitors (PPIs). Antiplatelet efficacy, at least in vivo, and particularly for clopidogrel, has been shown to be reduced with concomitant proton pump inhibitor use. Whether this is clinically relevant is not clear from the limited studies available.

Methods: We conducted an extensive review of studies available on Medline related to pharmacodynamic interactions between the antiplatelet medications and proton pump inhibitors as well as clinical studies that addressed this potential interaction.

Results: Based on the present pharmacodynamic and clinical studies we did not find a significant interaction that would reduce the efficacy of antiplatelet agents with concomitant user of proton pump inhibitors.

Conclusions: Patients on antiplatelet agents after a transient ischemic attack or ischemic stroke can safely use aspirin, and extended release dipyridamole/aspirin with proton pump inhibitors. Patients on clopidogrel may use other acid-reducing drugs besides proton pump inhibitors. In rare cases where proton pump inhibitors and clopidogrel have to be used concurrently, careful close monitoring for recurrent vascular events is required.

Keywords: proton pump inhibitors, antiplatelet medications, clopidogrel, ischemic stroke, cardiovascular events






 

Other articles by Dr Majaz Moonis



Readers of this article also read:

Pharmacogenomic application of the haptoglobin genotype in the treatment of HDL dysfunction
Pharmacogenomics in cardiovascular disorders: Steps in approaching personalized medicine in cardiovascular medicine
Pharmacogenomics in osteoporosis: Steps toward personalized medicine
Gene polymorphisms in association with self-reported stroke in US adults
Impact of genetic polymorphisms on clinical response to antithrombotics
The molecular mechanisms and pharmacotherapy of ATP-sensitive potassium channel gene mutations underlying neonatal diabetes
Pharmacogenomics of drug metabolizing enzymes and transporters: implications for cancer therapy
Role of cytochrome P450 genotype in the steps toward personalized drug therapy
The role of genetics in pre-eclampsia and potential pharmacogenomic interventions
Clinical applications of schizophrenia genetics: genetic diagnosis, risk, and counseling in the molecular era